Gemifloxacin (Factive)

A naphthyridine and fluoroquinolone derivative antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used for the treatment of community-acquired pneumonia and acute bacterial infections associated with chronic bronchitis.

Also Known As:

Factive; 7-(3-aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid; Gemifloxacin Mesylate; LB 20304; LB-20304; LB20304; SB 265805; SB-265805; SB265805; 1,8-Naphthyridine-3-carboxylic acid, 7-((4Z)-3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-

Networked: 138 relevant articles (23 outcomes, 32 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        Fluoroquinolones: 5348
        Gemifloxacin: 138
    - Naphthyridines: 2
      - Gemifloxacin: 138

Experts

1.	Ball, P: 5 articles (05/2004 - 07/2000)
2.	Tillotson, Glenn: 4 articles (04/2008 - 02/2004)
3.	Aguilar, L: 4 articles (02/2005 - 02/2000)
4.	Woodnutt, G: 4 articles (07/2000 - 03/2000)
5.	Blondeau, Joseph M: 3 articles (12/2009 - 05/2004)
6.	Tillotson, Glenn S: 3 articles (12/2009 - 12/2004)
7.	Hoban, Daryl J: 3 articles (12/2007 - 01/2002)
8.	Zhanel, George G: 3 articles (12/2007 - 01/2002)
9.	File, Thomas M: 3 articles (07/2007 - 11/2002)
10.	Mandell, L: 3 articles (02/2006 - 06/2001)

Related Diseases

1.	Infections 01/01/2019 - "Our study suggested that the administration of gemifloxacin according to drug levels in plasma to treat local infection is unreasonable and might result in an inadequate dose regimen." 12/01/2009 - "Young women with uncomplicated urinary infections were evaluated in two random clinical studies; they were treated with 320 mg gemifloxacin once a day for three days. " 08/01/2003 - "This study confirms the enhanced potent activity of gemifloxacin against Gram-positive pathogens, its broad-spectrum, Gram-negative activity and indicates that gemifloxacin is likely to have an important role in treating patients with Gram-positive and/or Gram-negative infections." 12/01/2009 - "Gemifloxacin is a flouroquinolon with an excellent in vitro activity against many community acquired bacteria which cause respiratory or urinary infections. " 09/01/2004 - "This early action of gemifloxacin should decrease the spread of infection and the inflammatory response since the tissue destruction process was attenuated at 4 h."
2.	Respiratory Tract Infections (Respiratory Tract Infection) 07/01/2001 - "An open-label, non-comparative study assessed the clinical and bacteriological efficacy of gemifloxacin (320 mg, once-daily for 7 days) in lower respiratory tract infections (LRTI). " 07/01/2000 - "The efficacy of gemifloxacin, in comparison with other oral agents used to treat respiratory infections, has also been evaluated in a rat model using doses, and therefore AUC0-24h/MIC ratios, that approximate those in man. " 06/01/2019 - "Gemifloxacin given once daily for 5-7 days has been shown to be non-inferior to, or in some instances superior to, comparator agents for the treatment of common lower respiratory tract infections. " 04/01/2008 - "Role of gemifloxacin in the management of community-acquired lower respiratory tract infections." 12/01/2006 - "Gemifloxacin demonstrated excellent clinical success in community-acquired lower respiratory infections, has an acceptable safety profile, and is a cost-effective alternative in the management of LRTIs including those caused by resistant pathogens."
3.	Pneumonia (Pneumonitis) 03/01/2013 - "The study group included patients with culture-confirmed pulmonary TB who initially received gemifloxacin for suspected community-acquired pneumonia (CAP). " 07/01/2012 - "Patients with clinical features of community acquired pneumonia (CAP) who fulfilled the inclusion criteria received treatment with oral gemifloxacin 320 mg once daily for 5-7 days. " 07/01/2012 - "Efficacy and safety of oral gemifloxacin for the empirical treatment of pneumonia." 08/01/2008 - "Role of gemifloxacin in community-acquired pneumonia." 05/01/2008 - "Gemifloxacin for community-acquired pneumonia."
4.	Chronic Bronchitis 01/01/2009 - "Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis." 05/01/2005 - "In clinical studies involving both hospitalized and outpatient populations, gemifloxacin has been highly effective in the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis. " 02/01/2012 - "The aim of the study was to evaluate the comparative effectiveness and safety of gemifloxacin for the treatment of patients with community-acquired pneumonia (CAP) or acute exacerbation of chronic bronchitis (AECB). " 02/01/2012 - "Gemifloxacin for the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis: a meta-analysis of randomized controlled trials." 07/01/2004 - "To evaluate the microbiology, pharmacokinetic parameters, drug interactions, and results of the available clinical trials of gemifloxacin for the treatment of community-acquired pneumonia (CAP) and acute exacerbation of chronic bronchitis (AECB). "
5.	Keratitis 10/01/2016 - "Ex vivo efficacy of gemifloxacin in experimental keratitis induced by methicillin-resistant Staphylococcus aureus." 08/01/2012 - "Efficacy of gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis." 10/01/2016 - "In this study, the antibacterial activity of gemifloxacin against MRSA ocular isolates in vitro and in a modified ex vivo rabbit keratitis model was investigated. " 08/01/2012 - "The objective of the present study was to evaluate the effectiveness of topically applied gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis in a rabbit model. " 10/01/2016 - "Results from the ex vivo keratitis model showed a statistically significant decrease in MRSA counts (0.5-2 log10 CFU/g; P <0.05) in corneas treated with 0.3% gemifloxacin every 30 min for 7 h. "

Related Drugs and Biologics

1.	Fluoroquinolones
2.	Levofloxacin (Levaquin)
3.	trovafloxacin
4.	Moxifloxacin (Avelox)
5.	Ciprofloxacin (Cipro)
6.	Clarithromycin (Biaxin)
7.	Azithromycin (Zithromax)
8.	Quinolones
9.	Anti-Infective Agents (Microbicides)
10.	grepafloxacin (Raxar)

Related Therapies and Procedures

1.	Therapeutics
2.	Punctures
3.	Lasers (Laser)
4.	Drug Therapy (Chemotherapy)
5.	Oral Administration